Anti-GCA Polyclonal Antibody

Catalog No.

PHD79801

Species reactivity

Human, Mouse, Rat

Host species

Rabbit

Isotype

IgG

Clonality

Polyclonal

Immunogen

E. coli - derived recombinant Human GCA (Met1-Val139).

Tested applications

ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000

Target

Grancalcin,GCA,GCL

Purification

Purified by antigen affinity column.

Accession

P28676

Applications

ELISA, IHC, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Avelumab-based neoadjuvant therapy in patients with muscle-invasive bladder cancer (AURA Oncodistinct-004): a phase 2 multicenter clinical trial., PMID:40413024

Sexual dimorphism of lung immune-regulatory units imprint biased pulmonary fibrosis., PMID:40360692

Gut Microbiota Modulates Obesity-Associated Skeletal Deterioration Through Macrophage Aging and Grancalcin Secretion., PMID:40349163

Autoimmune neuro-ophthalmic disorders: pathophysiologic mechanisms and targeted biologic therapies., PMID:40298278

Glucocorticoid boluses followed by tocilizumab in giant cell arteritis patients: effects on peripheral blood monocytes and lymphocytes., PMID:40213553

Sonographic study on vessel wall remodelling of the cranial and axillary arteries in giant cell arteritis under treatment: implications for diagnosis of relapses and impact of tocilizumab treatment., PMID:40201971

Mitochondrial-Mediated Platelet Activation in Polymyalgia Rheumatica., PMID:40071558

Highlights from the plenary session: cellular and molecular mechanisms of disease (I)., PMID:40071418

Highlights from the breakout session: diagnosis and classification of vasculitis., PMID:40071410

Giant cell arteritis - New treatment targets at the horizon., PMID:40044516

Butyrate Ameliorates Graves' Orbitopathy Through Regulating Orbital Fibroblast Phenotypes and Gut Microbiota., PMID:40035727

Tolicizumab effectively controls giant cell arteritis and prevents recurrence of steroid-induced concomitant toxoplasmosis chorioretinitis., PMID:40010759

To prophylax or not to prophylax? The role of trimethoprim/sulfamethoxazole as a prophylactic agent in systemic vasculitis: the case of antineutrophil cytoplasmic antibody-associated vasculitis and giant cell arteritis., PMID:39945417

Prevalence and Clinical Characteristics of Vasculitis in the Alaska Native and American Indian Peoples of Alaska., PMID:39936239

A feasible treatment strategy for tapering subcutaneous tocilizumab in giant cell arteritis: a 24-month multi-center retrospective study., PMID:39924612

Relapses in giant cell arteritis treated with tocilizumab. Retrospective multicenter study of 407 patients in clinical practice., PMID:39899915

Longitudinal Study of SARS-CoV-2 Vaccinations and Infections in Patients with Gastrointestinal Cancer: Stabilizing Immune Responses and Neutralizing Emerging Variants with Variant-Adapted Antigen Exposures., PMID:39769379

Does tocilizumab eliminate inflammation in GCA? A cohort study on repeated temporal artery biopsies., PMID:39740930

Management of Relapses in Giant Cell Arteritis., PMID:39711085

Brain MRI volumetry and atrophy rating scales as predictors of amyloid status and eligibility for anti-amyloid treatment in a real-world memory clinic setting., PMID:39708177

DOXY do, or DOXY Don't? Syphilis and doxycycline post-exposure prophylaxis: A case report., PMID:39689342

Tocilizumab in cranial and extracranial giant cell arteritis: a national multicentre study of 471 cases., PMID:39658241

Targeting interleukin-6 pathways in giant cell arteritis management: A narrative review of evidence., PMID:39644981

Sustained drug-free remission in giant cell arteritis., PMID:39589919

Tocilizumab (TCZ) for Giant Cell Arteritis: Clinical Outcomes Following Relapses and TCZ Discontinuation Due to Adverse Events., PMID:39547687

Use of immunosuppressants and biologics in giant cell arteritis: Recommendations of the French Study Group for Large Vessel Vasculitis (GEFA)., PMID:39500637

Genes deregulated in giant cell arteritis by Nanostring nCounter gene expression profiling in temporal artery biopsies., PMID:39317454

[News on the treatment of large vessel vasculitis]., PMID:39302435

Macrophage-Hepatocyte Circuits Mediated by Grancalcin Aggravate the Progression of Metabolic Dysfunction Associated Steatohepatitis., PMID:39279458

Evaluation of tocilizumab-induced hypofibrinogenemia in rheumatology practice: a retrospective, real-life, single-center experience., PMID:39261372

Predictive biomarkers of response to tocilizumab in giant cell arteritis (GCA): correlations with imaging activity., PMID:39210189

Treatment of giant cell arteritis with ultra-short glucocorticoids and tocilizumab: results from the extension of the TOPAZIO study., PMID:39150490

[Polymyalgia rheumatica: What's new?]., PMID:39146754

New onset of giant cell arteritis with ischaemic optic neuropathy following the seventh dose of COVID-19 mRNA vaccination: A case report and literature review., PMID:39096515

Faster steroid-free remission with tocilizumab compared to methotrexate in giant cell arteritis: a real-life experience in two reference centres., PMID:39093541

Analysis of immunoglobulin organization and complexity in mink (Neovison vison)., PMID:39069110

Relapses in giant cell arteritis: Updated review for clinical practice., PMID:39048072

Magnetic resonance imaging to monitor disease activity in giant cell arteritis treated with ultra-short glucocorticoids and tocilizumab., PMID:39037916

Taper versus discontinuation of tocilizumab in patients with giant cell arteritis: Real-world experience from a tertiary center., PMID:38981187

Identification of two autoantigens recognised by circulating autoantibodies as potential biomarkers for diagnosing giant cell arteritis., PMID:38976303

Thrombosis in vasculitis: An updated review of etiology, pathophysiology, and treatment., PMID:38975109

Tocilizumab use in giant cell arteritis: comparing Pharmaceutical Benefits Scheme eligible and ineligible cases in South Australia., PMID:38953308

Cholestasis-induced phenotypic transformation of neutrophils contributes to immune escape of colorectal cancer liver metastasis., PMID:38951890

Current management of giant cell arteritis and its complications., PMID:38920090

Effectiveness Of Tocilizumab In Aortitis And Aneurysms Associated With Giant Cell Arteritis., PMID:38908981

The spectrum of giant cell arteritis through a rheumatology lens., PMID:38898105

Naïve Inflammatory Proteome Profiles of Glucocorticoid Responsive Polymyalgia Rheumatica and Rheumatic Arthritis Patients-Links to Triggers and Proteomic Manifestations., PMID:38793033

Temporal arteritis presenting as third nerve palsy - a case report and review of literature., PMID:38739224

Impaired IL-6-induced JAK-STAT signaling in CD4+ T cells associates with longer treatment duration in giant cell arteritis., PMID:38653164

Limb arteries involvement assessed by FDG/PET CT at diagnosis of giant cell arteritis and risk of relapse: An observational study., PMID:38631525

Document Download

Anti-GCA Polyclonal Antibody.pdf